⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431362 | 0.65 | — | — | |
| SCHEMBL5318324 | 0.52 | — | — | |
| SCHEMBL1190870 | 0.39 | — | — | |
| SCHEMBL23964 | 0.39 | — | — | |
| SCHEMBL2554291 | 0.36 | — | — | |
| SCHEMBL248228 | 0.36 | — | — | |
| SCHEMBL4175824 | 0.36 | — | — | |
| SCHEMBL16553398 | 0.26 | — | — | |
| SCHEMBL4093276 | 0.26 | — | — | |
| Hydrogen Sulfide SCHEMBL15941638 | 0.26 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118234720-A | Radiolabeled fibroblast activation protein ligand | 菲罗化学股份公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-3715350-B1 | ARYLPHOSPHINE OXIDES FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2024-05-08 | — | — | EP | disclosed |
| US-11958870-B2 | Spiro-containing platinum(II) emitters with tunable emission energies and syntheses thereof | THE UNIVERSITY OF HONG KONG (CN) | 2024-04-16 | — | — | US | disclosed |
| EP-3715343-B1 | DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2024-02-14 | — | — | EP | disclosed |
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116917278-A | Divalent fibroblast activation protein ligands for targeted delivery applications | 菲罗化学股份公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3492462-B1 | AMINO PYRIMIDINE COMPOUND FOR INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | SHENZHEN TARGETRX INC (CN) | 2023-08-30 | — | — | EP | disclosed |
| CN-116635037-A | Mountain lotus leaf apigenin analogue as antiviral agent | 香港浸会大学 | 2023-08-22 | — | — | CN | disclosed |
| US-20220389038-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX, INC. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11389463-B2 | Antiviral nucleoside reverse transcriptase inhibitor | SHENZHEN TARGETRX, INC. (CN) | 2022-07-19 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| EP-1828223-A4 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS INC (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| EP-1828223-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | Panacos Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060205697-A1 | Novel betulin derivatives, preparation thereof and use thereof | MYREXIS, INC. | 2006-09-14 | — | — | US | disclosed |
| WO-2006053255-A2 | NOVEL BETULIN DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | PANACOS PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-5059608-A | Anticonvulsants, antiischemic agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1991-10-22 | — | — | US | disclosed |
| EP-0336228-A1 | Tetrahydroisoquinolines and tetrahydrobenzazepines and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-11 | — | — | EP | disclosed |